Trabectedin, derived originally from a marine organism, treats two genuinely rare cancer types — liposarcoma and leiomyosarcoma — in patients whose disease has spread and cannot be surgically treated after they've already tried other anticancer medications, positioning it as a specialty, later-line therapy for a small but consistently underserved patient population that sarcoma-treatment centers specifically seek out.
- Approved indications: Liposarcoma or leiomyosarcoma that has metastasized and is unresectable, in patients previously treated with certain other anticancer medicines; also indicated for recurrent ovarian cancer not responding to prior therapy
- Mechanism: An alkylating agent that binds specific nucleobases in tumor-cell DNA, triggering a cascade that disrupts the cell cycle and causes cancer-cell death
- Buyer profile: Specialist sarcoma-oncology centers and gynecologic-oncology programs, given the rarity of both its primary indications
- Treatment setting: Administered exclusively in hospital or clinic settings with staff specifically trained in cancer chemotherapy administration
- Hepatotoxicity: Significant risk requiring liver function testing before every treatment cycle — contraindicated in patients with pre-existing liver disease without dose adjustment
- Fertility impact: Can impair fertility in both men and women — fertility discussion recommended before starting treatment
- Vaccination caution: Should not be combined with recent yellow fever or other live vaccines
- Cardiac risk: Heart problems are a recognized serious side effect requiring monitoring
- Pregnancy: Unsafe, can cause severe birth defects — effective contraception required during treatment; men with partners of reproductive potential should use contraception for at least 5 months after the final dose
Given how few institutions worldwide manage sarcoma or recurrent ovarian cancer at the volume that regularly requires this drug, we treat Trabectedin with the same supply-continuity priority we apply to our other rare-disease and specialty oncology products.
- Certification: WHO-GMP sourced manufacturing
- Batch-specific testing: Purity and potency validated per batch
- Specialty supply focus: Proactive manufacturer communication maintained given the drug's lower-volume, specialty-oncology positioning
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C) with careful handling protocols
- Coverage: Global export markets
- Tracking: Full shipment tracking included
- Institutional buyers: Specialist sarcoma-oncology and gynecologic-oncology center procurement
- Unregistered markets: Named-patient supply pathway available given its specialty, later-line therapy status
What is Trabectedin used for?
Treats liposarcoma, leiomyosarcoma, and recurrent ovarian cancer that hasn't responded to prior treatment.
Get Trabectedin price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Does it affect fertility?
Yes, it can impair fertility in both men and women — a fertility discussion with the treating physician is recommended before starting.
Can it be given at home?
No, it's administered only in a hospital or clinic setting by staff trained in cancer chemotherapy.
Who supplies Trabectedin from India?
WHO-GMP certified manufacturer with full export documentation.
